Folliculitis decalvans associated with erlotinib

Clinical and Experimental Dermatology

Volumn 35, Issue 8, 2010, Pages 916-918

  Hoekzema, R ^a   Drillenburg, P ^b  

^a Departments of Dermatology   (Netherlands)

^b Departments of Pathology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DESOXIMETASONE; ERLOTINIB; MINOCYCLINE; MOMETASONE FUROATE; POVIDONE IODINE;

ACNE; ADULT; CASE REPORT; FEMALE; FOLLICULITIS; FOLLICULITIS DECALVANS; HAIR GROWTH; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LUNG NON SMALL CELL CANCER; METASTASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE;

ALOPECIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLICULITIS; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; STAPHYLOCOCCUS AUREUS;

EID: 78149378865     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03852.x     Document Type: Letter

References (5)

1. Agero ALC, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70.
2. Kardaun SH, Van Duinen KF. Erlotinib-induced florid acneiform rash complicated by extensive impetiginisation. Clin Exp Dermatol 2007; 33: 46-9.
3. Wu CY, Chen GS, Lan CC. Erosive pustular dermatosis of the scalp after gefitinib and radiotherapy for brain metastases secondary to lung cancer. Clin Exp Dermatol 2008; 33: 106-7.
4. Donovan JC, Ghazarian DM, Shaw JC. Scarring alopecia associated with use of the epidermal growth factor inhibitor gefitinib. Arch Dermatol 2008; 144: 1524-5.
5. Ena P, Fadda GM, Ena L et al. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer. Clin Exp Dermatol 2008; 33: 790-1.